Saturday, 31 October 2026European Markets

THE NAVIGATOR COMP And ROBERTET Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(vianews) - the navigator comp (nvg.ls) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
the navigator comp (nvg.ls) €3.61 17.54% 31.56%
robertet (rbt.pa) €798.00 0.88% 18.41%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. the navigator comp (nvg.ls)

17.54% forward dividend yield and 31.56% return on equity

the navigator company, s.a. manufactures and markets pulp and paper products worldwide. the company operates through market pulp, uwf paper, tissue paper, and biomass renewable energy segments. it produces bleached eucalyptus kraft pulp, uncoated writing and printing thin paper, and domestic consumption paper under the navigator, multioffice, discovery, explorer, inacopia, target, pioneer, soporset, inaset, and target plus brands for professional and home use. the company also operates cogeneration units and two independent thermoelectric power plants. the company was formerly known as portucel, s.a. and changed its name to the navigator company, s.a. in february 2016. the navigator company, s.a. was founded in 1953 and is headquartered in setúbal, portugal. the navigator company, s.a. operates as a subsidiary of semapa - sociedade de investimento e gestão, sgps, s.a.

earnings per share

as for profitability, the navigator comp has a trailing twelve months eps of €0.42.

pe ratio

the navigator comp has a trailing twelve months price to earnings ratio of 8.6. meaning, the purchaser of the share is investing €8.6 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 31.56%.

growth estimates quarters

the company's growth estimates for the current quarter and the next is a negative 53.3% and a negative 76.5%, respectively.

more news about the navigator comp.

2. robertet (rbt.pa)

0.88% forward dividend yield and 18.41% return on equity

robertet sa produces and sells perfumes, aromas, and natural products. the company operates in four segments: raw materials, fragrances, flavors, and active ingredients. it also produces organic essential oils and active ingredients. the company operates in north america, europe, the asia pacific, south america, caribbean, africa, and the middle east. robertet sa was founded in 1850 and is headquartered in grasse, france.

earnings per share

as for profitability, robertet has a trailing twelve months eps of €36.02.

pe ratio

robertet has a trailing twelve months price to earnings ratio of 22.15. meaning, the purchaser of the share is investing €22.15 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.41%.

more news about robertet.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com